Table – Description of all patient-characteristics assessed for the study, rates of virologic success, unadjusted and adjusted ORs of patients' characteristics for virologic success.

Baseline Characteristics	N = 191 (%)	Virologic Success (%)	OR (95%CI)	p-value	aOR (95%CI)	Adjusted p-value
Facility type						
– Health Center	79 (41.4%)	58 (73.4%)	Ref	0.762		
– District Hospital	112 (58.6%)	80 (71.4%)	0.91 (0.47-1.74)			
Age at cART-start (years)						
– < 2	41 (21.5%)	25 (61.0%)	Ref	0.247		
– 2-5	40 (20.9%)	30 (75.0%)	1.92 (0.60-6.12)			
– 5-10	73 (38.2%)	53 (72.6%)	1.70 (0.63-4.56)			
– 10-16	37 (19.4%)	30 (81.1%)	2.74 (0.78-9.67)			
Gender						
– Male	96 (50.3%)	68 (70.8%)	Ref	0.660		
– Female	95 (49.7%)	70 (73.7%)	1.15 (0.61-2.19)			
Clinical WHO-stage at baseline						
– Stage 1 or 2	121 (63.4%)	83 (68.6%)	Ref	0.046	Ref	0.221
– Stage 3 or 4	66 (34.6%)	54 (81.8%)	2.06 (1.00-4.32)		1.66 (0.71-3.85)	
– missing information	4 (2.1%)	1 (25.0%)				
Immunological stage at baseline						
– Severe immunodeficiency	44 (23.0%)	34 (79.5%)	Ref	0.311		
– Advanced immunodeficiency	50 (26.2%)	34 (68.0%)	0.63 (0.20-1.93)			
– No immunodeficiency	54 (28.3%)	40 (74.1%)	0.84 (0.27-2.62)			
– missing information	25 (13.1%)	14 (56.0%)				
Hemoglobin at baseline (g/dL)						
– < 10	28 (14.7%)	19 (67.9%)	Ref	0.536		
– 10-11.9	53 (27.8%)	40 (75.5%)	1.46 (0.46-4.64)			
– ≥ 12	53 (27.8%)	42 (79.3%)	1.81 (0.55-5.92)			
– missing information	57 (29.8)	37 (64.9%)				
Social Characteristics						
Orphanhood						
– both parents alive	77 (40.3%)	50 (64.9%)	Ref	0.066	Ref	0.584
– single orphan	75 (39.3%)	61 (81.3%)	2.35 (0.99-5.56)		1.56 (0.58-4.18)	

− double orphan	36 (18.9%)	25 (69.4%)))	1.23 (0.46-3.27)		1.16 (0.36-3.72)	
− missing information	3 (1.6%)	2 (66.7%)				
Household Wealth-Quintile¶						
− 1st (lowest)	39 (20.4%)	26 (66.7%)	Ref	0.626		
− 2nd	38 (19.9%)	25 (65.8%)	0.96 (0.29-3.22)			
− 3rd	38 (19.9%)	29 (76.3%)	1.61 (0.45-5.80)			
− 4th	38 (19.9%)	28 (73.7%)	1.40 (0.40-4.92)			
− 5th (highest)	38 (19.9%)	30 (78.9%)	1.88 (0.50-6.96)			
Travel-time to facility (hours)						
− < 0.5 hourhours	56 (19.2)%	40 (71.4%)	Ref	0.397		
− 0.5-1 hour	54 (38.7%)	39 (72.2%)	1.04 (0.38-2.87)			
− 1 – 2	55 (28.8%)	42 (76.4%)	1.29 (0.46-3.640)			
Travel-mode to facility						
− Walk	110 (57.6%)	78 (70.9%)	Ref	0.786		
− Taxi/public transport	77 (40.3%)	56 (72.7%)	1.09 (0.57-2.11)			
− Other	4 (2.1%)	4 (100%)				
No. of persons disclosed to						
− 1-3	60 (31.4%)	44 (73.3%)	Ref	0.388		
− 6-10	45 (23.6%)	32 (71.1%)	0.90 (0.31-2.56)			
− > 10	39 (20.4%)	28 (71.8%)	0.93(0.31-2.78)			
− Missing information	2 (1.0%)	1 (50.0%)				
Adherence						
Visual Analogue Scale						
− ≥ 95%	101 (52.9%)	78 (77.2%)	Ref	0.107	Ref	0.107
− < 95%	87 (45.5%)	58 (66.7%)	0.59 (0.31-1.13)		0.70 (0.33-1.49)	
− missing information	3 (1.6%)	2 (66.2)				
Pill-Count						
− ≥ 95%	118 (61.8%)	84 (71.2%)	Ref	0.475		
− < 95%	51 (26.7%)	39 (76.5%)	1.32 (0.61-2.84)			
− missing information	22 (11.5%)	15 (68.2%)				
History of cART interruption ≥ 2 days						
No	168 (87.9%)	127 (75.6%)	Ref	0.004	Ref	0.120
Yes	19 (9.9%)	8 (42.1%)	0.23 (0.09-0.63)		0.40 (0.12-1.31)	
missing information	4 (2.1%)	3 (75.0%)				

Biomedical Characteristics at enrollment						
Time on cART (years)						
− 0.5-1.9	45 (23.6%)	32 (71.1)%	Ref	0.506		
− 2-3.4	46 (24.1%)	33 (71.7%)	1.03 (0.34-3.12)			
− 3.5-4.9	44 (23.0%)	28 (63.6%)	0.71 (0.24-2.10)			
− ≥ 5	56 (29.3%)	45 (80.4%)	1.66 (0.54-5.11)			
cART-base						
− EFV	80 (41.9%)	67 (83.8%)	Ref	0.003	Ref	0.012
− NVP	100 (52.4%)	64 (64.0%)	0.34 (0.17-0.72)		0.37 (0.16-0.85)	
− LPV/r	8 (4.2%)	4 (50.0%)				
− missing information	3 (1.6%)	3 (100%)				
cART-backbone						
− AZT/3TC	166 (86.9%)	121 (72.9%)				
− TDF/3TC	6 (3.1%)	4 (66.7%)				
− ABC/3TC	8 (4.2%)	6 (75.0%)				
− missing information	11 (5.8%)	7 (63.6%)				
Assessment at study visit						
Clinical Failure (WHO 3 or 4 event)	6 (3.1%)	4 (66.7%)				
Currently on tuberculosis therapy	5 (2.6%)	3 (60.0%)				
Weight for age (if age<10 years, n=100)						
− WAZ ≥ -2 at study visit	76 (76.0%)	57 (75.0%)	Ref	0.125		
− WAZ < -2 at study visit	24 (24.0%)	14 (58.3%)	0.47 (0.17-1.25)			
Height for age at study visit						
− HAZ ≥ -2 at study visit	74 (38.7%)	53 (71.6%)	Ref	0.888		
− HAZ <-2 at study visit	113 (59.2%)	82 (72.6)%	1.05 (0.54-2.03)			
− missing information	4 (1.4%)	3 (75.0%)				
BMI for Age at study-visit						
− BAZ ≥-2 at study visit	174 (91.1%)	124 (71.3%)	Ref	0.273		
− BAZ <-2 at study visit	13 (6.8%)	11 (84.6%)	2.21 (0.47-10.56)			
− missing information	4 (2.1%)	3 (75.0%)				
Hemoglobin at study visit (g/dL) (iqr)						
− < 10	3 (1.6%)	2 (66.7%)		0.343		
− 10-11.9	30 (15.7%)	19 (63.3%)	Ref			

− ≥ 12	153 (80.1%)	115 (75.2%)	1.75 (0.76-4.05)	0.192		
− missing information	5 (2.6%)	2 (40.0%)				
Immunological situation at study-visit						
Immunological staging						
− Severe immunodeficiency	9 (4.7%)	2 (22.2%)				
− Advanced immunodeficiency	7 (3.7%)	1 (14.3%)				
− Mild immunodeficiency	11 (5.8%)	6 (54.5%)				
− No immunodeficiency	157 (82.2%)	126 (80.3%)				
− Missingmissing information	7 (3.7%)	3 (42.9%)				
Immunologic failure						
− No immunological failure	179 (93.7%)	135 (75.4%)				
− CD4-count<100 or CD4%<10%	5 (2.6%)	0				
− missing information	7 (3.7%)	3 (42.9%)				

Abbreviations: WAZ: Weight-for-age Z-score; HAZ: Height-for-age Z-score; BAZ: BMI-for-age Z-score; BMI: Body-mass-index; cART: combination antiretroviral therapy; WHO: World Health Organization.

¶ Household wealth was assessed using the Wealth Index of the Lesotho Demograhic and Health Survey 2009 [17]